The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council

Detalles Bibliográficos
Autores principales: Agboola, Foluso, Lin, Grace A., Fluetsch, Noemi, Walton, Surrey M., Rind, David M., Pearson, Steven D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Perspectives on Value
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391264/
https://www.ncbi.nlm.nih.gov/pubmed/32223597
http://dx.doi.org/10.18553/jmcp.2020.26.4.361
_version_ 1785082667427954688
author Agboola, Foluso
Lin, Grace A.
Fluetsch, Noemi
Walton, Surrey M.
Rind, David M.
Pearson, Steven D.
author_facet Agboola, Foluso
Lin, Grace A.
Fluetsch, Noemi
Walton, Surrey M.
Rind, David M.
Pearson, Steven D.
author_sort Agboola, Foluso
collection PubMed
description
format Online
Article
Text
id pubmed-10391264
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103912642023-08-02 The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council Agboola, Foluso Lin, Grace A. Fluetsch, Noemi Walton, Surrey M. Rind, David M. Pearson, Steven D. J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2020-04 /pmc/articles/PMC10391264/ /pubmed/32223597 http://dx.doi.org/10.18553/jmcp.2020.26.4.361 Text en Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Perspectives on Value
Agboola, Foluso
Lin, Grace A.
Fluetsch, Noemi
Walton, Surrey M.
Rind, David M.
Pearson, Steven D.
The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_full The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_fullStr The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_full_unstemmed The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_short The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_sort effectiveness and value of deflazacort and exon-skipping therapies for the management of duchenne muscular dystrophy: a summary from the institute for clinical and economic review’s new england comparative effectiveness public advisory council
topic Perspectives on Value
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391264/
https://www.ncbi.nlm.nih.gov/pubmed/32223597
http://dx.doi.org/10.18553/jmcp.2020.26.4.361
work_keys_str_mv AT agboolafoluso theeffectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT lingracea theeffectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT fluetschnoemi theeffectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT waltonsurreym theeffectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT rinddavidm theeffectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT pearsonstevend theeffectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT agboolafoluso effectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT lingracea effectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT fluetschnoemi effectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT waltonsurreym effectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT rinddavidm effectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT pearsonstevend effectivenessandvalueofdeflazacortandexonskippingtherapiesforthemanagementofduchennemusculardystrophyasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil

Ejemplares similares